Sertindole is associated with a low level of extrapyramidal symptoms in schizophrenic patients: Results of a phase III trial

International Journal of Psychiatry in Clinical Practice

Volumn 4, Issue 1, 2000, Pages 47-54

  Hale, Anthony ^a   Azorin, Jean Michel ^b   Kasper, Siegfried ^d   Maier, Wolfgang ^c   Syvälahti, Erkka ^d   Van Der Burght, Michael ^e   Sloth Nielsen, Mogens ^e   Wehnert, Allan ^e  

^a UNIVERSITY OF KENT   (United Kingdom)

^b HÔPITAL SAINTE MARGUERITE   (France)

^c UNIVERSITY HOSPITAL BONN   (Germany)

^d Dept Pharmacol Clin Pharmacol ^*

^e H LUNDBECK A S   (Denmark)

Author keywords

Antipsychotic agents; Extrapyramidal symptoms; Phase III clinical trial; Schizophrenia; Sertindole

Indexed keywords

NEUROLEPTIC AGENT; PLACEBO; SERTINDOLE;

ADULT; AKATHISIA; ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERANCE; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MOTOR DYSFUNCTION; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PSYCHOSIS; RATING SCALE; SCHIZOPHRENIA; SEDATION;

EID: 0034074870     PISSN: 13651501     EISSN: None     Source Type: Journal    
DOI: 10.1080/13651500052048758     Document Type: Article

References (31)

1. Bunney BS (1984) Antipsychotic drug effects on the electrical activity of dopaminergic neurons. Trends Neurosci (June) 212-215.
2. 2 receptor occupancy studies and clinical response. Br J Psychiatry 168 (Suppl 29): 40-44.
3. Casey DE (1991) Neuroleptic drug-induced extrapyramidal syndromes and tardive dyskinesia. Schizophr Res 4: 109-120.
4. Casey DE, Keepers GA (1988) Neuroleptic side effects: acute extrapyramidal syndromes and tardive dyskinesia. In: Vibeke Christensen DE and A (eds) Psychophannacology: Current Trends. Springer, Berlin: 74-93.
5. Saltz BL, Woerner M, Kane JM (1991) Prospective study of tardive dyskinesia incidence in the elderly. JAMA 266: 2402-2406.
6. Skarsfeldt T, Perregaard J (1990) Sertindole, a new neuroleptic with extreme selectivity on AlO versus A9 dopamine neurones in rats. Eur J Pharmacol 182: 613-614.
7. Sánchez C, Arnt J, Dragsted N (1991) Neurochemical and in vivo pharmacological profile of sertindole, a limbic-selective neuroleptic compound. Drug Dev Res 22: 239-242.
8. 2 and serotonin mechanisms. In: Fog R, Gerlach J, Hemmingsen R (eds) Schizophrenia: An Integrated View. Munksgaard, Copenhagen: 287-298.
9. Tamminga CA, Mack RJ, Granneman GR et al (1997) Sertindole in the treatment of psychosis in schizophrenia: efficacy and safety. Int Clin Psychopharmacol 12 (Suppl 1): S29-S35.
10. th Annual Meeting 1995. American College of Neuropsycopharmacology, Nashville, TN (abstract 278).
11. van Kammen DP, McEvoy JP, Targum SD et al (1996) A randomized, controlled, dose-ranging trial of sertindole in patients with schizophrenia. Psychopharmacology 124: 168-175.
12. Zimbroff D, Kane JM, Tamminga CA et al (1997) A controlled, dose-response study of sertindole and haloperidol in schizophrenia. Am J Psychiatry 154 (Suppl 6): 782-791.
13. Hale AS, Azorin J-M, Maier W et al (2000). Sertindole controls both the positive and negative symptoms of schizophrenia: results of a phase III trial. Int J Psychiatry Clin Pract 4: 55-62.
14. Kay SR, Fisbein A, Opler LA (1987) The Positive and Negative Syndrome Scale (PANNS) for schizophrenia. Schizophr Bull 13: 261-276.
15. Simpson G, Angus JSW (1970) A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 212 (Suppl): 11-19.
16. Guy W (1976) ECDEU Assessment Manual for Psychopharmacology. Publication (ADM) 76-338: US Department of Health and Human Services, Rockville, MD. 534-535.
17. van Putten T, Marder SR, Mintz J et al (1992) Haloperidol plasma levels and clinical response: a therapeutic window relationship. Am J Psychiatry 149: 510-515.
18. Barnes TR (1989) A rating scale for drug-induced akathisia. Br J Pharmacol 154: 672-676.
19. Meltzer HY, Matsubara S, Lee JC (1989) Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin pKi values. J Pharmacol Exp Ther 251: 238-246.
20. Casey DE (1989) Clozapine: neuroleptic-induced EPS and tardive dyskinesia. Psychopharmacology (Berl) 99 (Suppl): S47-S53.
21. Casey DE (1996) Behavioral effects of sertindole, risperidone, clozapine and haloperidol in cebus monkeys. Psychopharmacology 124: 134-140.
22. Marder SR, Meibach RC (1994) Risperidone in the treatment of schizophrenia. Am J Psychiatry 151: 825-835.
23. Beasley CM (1997) Letter to the editor-reply. Neuropsychopharmacology 16: 163.
24. Ames D, Wirshing WC, Marder SR (1996) Advances in antipsychotic pharmacotherapy: clozapine, risperidone and beyond. Essen Psychopharmacol 1: 5-26.
25. Schultz S, Miller D, Arndt S et al (1995) Withdrawal-emergent dyskinesia in patients with schizophrenia during antipsychotic discontinuation. Soc Biol Psychiatry 38: 713-719.
26. Weiden PJ, Aquila R, Dalheim L et al (1997) Switching antipsychotic medications. J Clin Psychiatry 58 (Suppl 10): 63-72.
27. Wehnert A, Stilwell C, Rasmussen C et al (1997) Extrapyramidal symptoms and sertindole-analysis of three double-blind, haloperidol-referenced, phase III clinical trials. Euro Neuropsychopharmacology 7: (S2), S218. Poster presentations at the Xth ECNP congress, September 13-17, 1997, Vienna, Austria.
28. Wehnert A, Stilwell C, Rasmussen C et al (1997) Extrapyramidal symptoms and sertindole-analysis of three double-blind, haloperidol-referenced, phase III clinical trials. Euro Neuropsychopharmacology 7: (S2), S218. Poster presentations at the Xth ECNP congress, September 13-17, 1997, Vienna, Austria.
29. Fogelson DL, Sternback H, Dayne D (1997) A naturalistic pilot study comparing haloperidol, clozapine, sertindole and risperidone in partially responsive chronic schizophrenia or schizoaffective disorders. J Clin Psychopharmacol 17: 492-494.
30. Ben-David J, Zipes DP (1993) Arrhythmia octet: torsade de pointes and proarrhythmia. Lancet 341: 32-36.
31. Kasper S, Hale A, Azorin J-M, Möller H-J (1999) Benefit-risk evaluation of olanzapine, risperidone and sertindole in the treatment of schizophrenia. Eur Arch Psychiatry Clin Neurosci 249 (Suppl 2): II/2-II/14.